PHARMACOECONOMIC PROGNOSIS FOR LONG-TERM TREATMENT OF ALZHEIMER PATIENTS WITH AKATINOL (MEMANTINE)
Pharmacoeconomic modeling of a 5-year akatinol (memantine) medication of moderate to severe Alzheimer patients point to superiority of akatinol to standard (conventional) treatments used in regular psychiatric practice because these patients show lower risk of hospitalization or placement to a psychoneurological residential facility. Sensitive analysis emphasizes the dependence of the modeling results on the bed turnover parameter and the percentage of patients in residential nursing facilities.